The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
The development of generic versions of innovator medicines is a global public health need.
In the U.S. and around the world, quality standards developed by the U.S. Pharmacopeia (USP) support the availability of safe, quality medicines, regulatory efficiencies, and a strong global medicine supply chain.
In Nigeria, mothers frequently deliver their babies at home—only 36 percent deliver at health care facilities. Giving birth without the assistance of trained healthcare providers leaves babies vulnerable to infections, and some can be fatal.
In conversations about the role of quality standards in public health, you might come across the words “compendia” and “compendial.” At USP, terms like “compendial approaches,” “compendial standards,” and “compendial tools” are part of our everyday vocabulary.
The opioid crisis in the U.S. seems to be part of nearly every news broadcast and news site today. And based on the number of people affected by this crisis, serious conversations about how to help are more important than ever.